Nicholas D. Socci

Memorial Sloan Kettering Cancer Center

Full Professor(heuristic)

Cancer Genomics and Diagnostics · Cancer Research

h-index111

i10-index209

Publications872

Citations66,216

Grants

No NSF/NIH grants on record.

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

Potential Collaborators

Recent Publications

Last 2 years · showing 20 of 143

Targeting eIF4A-dependent translation in genetically complex sarcoma
JCI Insight · 2026-04-07
A transposase-derived gene required for human brain development
Science Advances · 2026-01-14 · 1 citations
Supplementary Tables S1-S2 from Moving Spatially Resolved Multiplexed Protein Profiling toward Clinical Oncology
2025-12-11
Supplementary Figure 4 from Molecular Characterization of Acquired Resistance to KRAS<sup>G12C</sup>–EGFR Inhibition in Colorectal Cancer
2025-12-10
Supplementary Figure 1 from Molecular Characterization of Acquired Resistance to KRAS<sup>G12C</sup>–EGFR Inhibition in Colorectal Cancer
2025-12-10
Supplementary Table 2 from Molecular Characterization of Acquired Resistance to KRAS<sup>G12C</sup>–EGFR Inhibition in Colorectal Cancer
2025-12-10
Supplementary Figure 2 from Molecular Characterization of Acquired Resistance to KRAS<sup>G12C</sup>–EGFR Inhibition in Colorectal Cancer
2025-12-10
Supplementary Table 3 from Molecular Characterization of Acquired Resistance to KRAS<sup>G12C</sup>–EGFR Inhibition in Colorectal Cancer
2025-12-10
Supplementary Figure 5 from Molecular Characterization of Acquired Resistance to KRAS<sup>G12C</sup>–EGFR Inhibition in Colorectal Cancer
2025-12-10
Supplementary Figure 6 from Molecular Characterization of Acquired Resistance to KRAS<sup>G12C</sup>–EGFR Inhibition in Colorectal Cancer
2025-12-10
Supplementary Table 1 from Molecular Characterization of Acquired Resistance to KRAS<sup>G12C</sup>–EGFR Inhibition in Colorectal Cancer
2025-12-10
Supplementary Figure 3 from Molecular Characterization of Acquired Resistance to KRAS<sup>G12C</sup>–EGFR Inhibition in Colorectal Cancer
2025-12-10
Table S5 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
2025-11-25
Table S6 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
2025-11-25
Table S2 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
2025-11-25
Table S4 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
2025-11-25
Table S1 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
2025-11-25
Supplementary Table S1 from Overcoming Barriers to Tumor Genomic Profiling through Direct-to-Patient Outreach
2025-11-25
Figure S3 from Genomic and Transcriptomic Characteristics of Metastatic Thyroid Cancers with Exceptional Responses to Radioactive Iodine Therapy
2025-11-25
Supplementary Table S2 from Overcoming Barriers to Tumor Genomic Profiling through Direct-to-Patient Outreach
2025-11-25

Open author page on OpenAlex →